NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Tempest Therapeutics, Inc. (TPST) Stock Analysis

Tempest Therapeutics, Inc. (TPST) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TPST

$1.03

−$0.02 (−1.90%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TPST with… →

TPST Key Statistics

As of Sep 4, 2026
Trading
Open
$1.04
Previous Close
$1.05
Day's Range
1.01–1.05
52-Week Range
0.84–12.23
Volume
214.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.66
Valuation
Market Cap
$17.04M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.68
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$26.26M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
16.54M
1-Year Return
−89.73%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
208.17K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TPST Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−64.11%
2025−73.56%
2024−81.02%
2023+282.61%
2022−78.22%
2021−83.55%
2020−68.25%
2019−15.22%
2018−62.14%
2017−8.50%
2016 (partial year)−74.58%

As of September 4, 2026.

TPST Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$26.26M—
2024$0.00−$41.84M—
2023$0.00−$29.49M—
2022$0.00−$35.71M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$26.58M−$26.26M—
2024$0.00—−$42.03M−$41.84M—
2023$0.00—−$29.16M−$29.49M—
2022$0.00—−$34.64M−$35.71M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TPST Valuation vs Biotechnology Median

Median of 656 stocks
MetricTPSTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tempest Therapeutics, Inc. (TPST) carries a market capitalisation of $17.04M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 4.

The 52-week range on file runs from $0.84 to $12.23. The most recent close on file for TPST is $1.03, dated September 4, 2026. That is −$0.02 (−1.90%) against the previous close. The latest close sits 22.62% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $26.26M. Profit margin runs at 0%. Trailing earnings per share are −3.68.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at −1.66. Annualized volatility over the trailing 10 years is 1,261.88%. The trailing one-year price return is −89.73%. Measured over 10 years, that is −62.45% a year compounded.

Growth & Income

No dividend is on file for TPST.

2026 is still running; the price is −64.11% year to date. Across the complete calendar years on file, 2023 returned +282.61% and 2021 returned −83.55%. Of the 9 complete calendar years on file, 1 finished higher.

Peer Comparison

Tempest Therapeutics, Inc. (TPST) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tempest Therapeutics, Inc. TPST $17.04M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Tempest Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Visit website →